Autoimmune Diabetes
22
5
7
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
4.5%
1 terminated out of 22 trials
87.5%
+1.0% vs benchmark
18%
4 trials in Phase 3/4
71%
5 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (22)
Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes
Intensive Dietary and Activity Counselling (IDAC)
Metabolic and Immunoinflammatory Profiles in Adults With Newly Diagnosed Diabetes
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus
Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth
Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)
Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes
Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance
Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA
Is the Artificial Pancreas, Without Carbohydrate Counting, Efficient and Safe in an Outpatient Setting
Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus
Metformin Plus Insulin on Non-obese Autoimmune Diabetes
Medtronic Minimed Overnight Closed-Loop System
Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus